Share This Page
METHOTREXATE SODIUM PRESERVATIVE FREE Drug Patent Profile
✉ Email this page to a colleague
When do Methotrexate Sodium Preservative Free patents expire, and when can generic versions of Methotrexate Sodium Preservative Free launch?
Methotrexate Sodium Preservative Free is a drug marketed by Accord Hlthcare, Caplin One Labs, Eugia Pharma Speclts, Extrovis, Hikma, Hospira, Pharmachemie Bv, and Sagent Pharms Inc. and is included in thirteen NDAs.
The generic ingredient in METHOTREXATE SODIUM PRESERVATIVE FREE is methotrexate sodium. There is one drug master file entry for this compound. Thirty suppliers are listed for this compound. Additional details are available on the methotrexate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Methotrexate Sodium Preservative Free
A generic version of METHOTREXATE SODIUM PRESERVATIVE FREE was approved as methotrexate sodium by HIKMA on September 16th, 1986.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for METHOTREXATE SODIUM PRESERVATIVE FREE?
- What are the global sales for METHOTREXATE SODIUM PRESERVATIVE FREE?
- What is Average Wholesale Price for METHOTREXATE SODIUM PRESERVATIVE FREE?
Summary for METHOTREXATE SODIUM PRESERVATIVE FREE
| US Patents: | 0 |
| Applicants: | 8 |
| NDAs: | 13 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,127 |
| DailyMed Link: | METHOTREXATE SODIUM PRESERVATIVE FREE at DailyMed |
Recent Clinical Trials for METHOTREXATE SODIUM PRESERVATIVE FREE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cooperative Study Group A for Hematology | Phase 3 |
See all METHOTREXATE SODIUM PRESERVATIVE FREE clinical trials
Pharmacology for METHOTREXATE SODIUM PRESERVATIVE FREE
| Drug Class | Folate Analog Metabolic Inhibitor |
| Mechanism of Action | Folic Acid Metabolism Inhibitors |
US Patents and Regulatory Information for METHOTREXATE SODIUM PRESERVATIVE FREE
# Methotrexate Sodium Preservative Free Market Dynamics and Financial Trajectory
Methotrexate sodium preservative free is a mature generic injectable used in oncology, rheumatology, dermatology, and ectopic-pregnancy treatment. Its market is driven by hospital demand, injectable manufacturing capacity, shortages, contract purchasing, and low generic pricing rather than patent exclusivity. Product-specific revenue is generally not disclosed because manufacturers report methotrexate within broader injectable or generic portfolios.
The commercial outlook is stable in baseline demand but exposed to supply disruptions. Preservative-free presentations are important for intrathecal administration and other clinical settings where benzyl alcohol or other preservatives are unsuitable. The highest financial sensitivity is therefore operational: sterile manufacturing capacity, quality compliance, raw-material availability, and hospital contract retention.
What is methotrexate sodium preservative free?
Methotrexate sodium preservative free is an injectable formulation of methotrexate without antimicrobial preservatives. It is supplied in single-dose vials, syringes, or other sterile presentations, depending on the manufacturer and market.
Methotrexate is a folate antagonist that inhibits dihydrofolate reductase and other folate-dependent pathways. Injectable use includes:
- Acute lymphoblastic leukemia and other hematologic malignancies
- Osteosarcoma and selected solid tumors
- Rheumatoid arthritis and psoriasis
- Ectopic pregnancy
- Intrathecal treatment in selected oncology protocols
The preservative-free attribute matters most for routes and settings where preservatives create safety or compatibility concerns. Product labels warn that formulations containing benzyl alcohol should not be used intrathecally. Preservative-free methotrexate is therefore a distinct procurement requirement in hospitals even when the active ingredient and strength are otherwise interchangeable.[1]
Common presentations and strengths
U.S. products have historically included injectable strengths such as:
| Presentation | Typical commercial use | Market characteristic |
|---|---|---|
| 25 mg/mL single-dose vial | Oncology, rheumatology, emergency use | Core hospital presentation |
| 50 mg/2 mL vial | Equivalent 25 mg/mL concentration | Procurement and packaging variation |
| 1 g/40 mL or larger vial | High-dose oncology | Lower-volume, higher-value use |
| Preservative-free syringe or specialty presentation | Selected institutional and specialty use | More limited competition |
Available presentations vary by manufacturer, National Drug Code, hospital contract, and FDA market status. Product selection must be based on strength, route, preservative status, concentration, container closure, and approved labeling.
How large is the methotrexate sodium preservative-free market?
The market is a small but strategically important segment of the broader methotrexate and generic injectable market. No authoritative public source provides a consolidated global revenue figure specifically for methotrexate sodium preservative free.
The market has four defining characteristics:
- Demand is recurring because methotrexate is embedded in standard oncology and rheumatology protocols.
- Unit prices are low for common generic vials.
- Hospital buyers place a high premium on supply continuity.
- A limited number of sterile injectable suppliers can create concentrated supply risk.
The total methotrexate market includes oral tablets, oral solutions, prefilled injections, autoinjectors, and preservative-containing or preservative-free vials. These products should not be combined in financial analysis because their pricing, channels, regulatory pathways, and competitive sets differ.
Demand drivers
Demand is supported by:
- Continued use of methotrexate in hematologic oncology
- Chronic rheumatoid arthritis treatment
- Dermatology use for psoriasis and related inflammatory disease
- Ectopic-pregnancy treatment
- Institutional protocols requiring preservative-free injectable products
- Increased oncology treatment volumes in hospitals and outpatient centers
Demand is relatively resilient because methotrexate is an established first-line or backbone therapy in several indications. Substitution risk exists, but clinical protocols and cost controls often preserve methotrexate use even when newer agents are available.
Demand constraints
Growth is limited by the maturity of the molecule and the availability of alternatives:
- Biologic and targeted therapies compete with methotrexate in rheumatoid arthritis and psoriasis.
- Oral methotrexate remains a lower-cost alternative for many non-oncology patients.
- High-dose oncology use depends on treatment volumes and institutional protocols.
- Hospitals can switch between equivalent generic suppliers when supply is available.
- Low pricing limits the ability of manufacturers to fund extensive commercial promotion.
What is the financial trajectory for methotrexate sodium preservative free?
The financial trajectory is best characterized as mature, low-growth, and supply-sensitive.
| Financial factor | Expected effect |
|---|---|
| Baseline demand | Stable to modest growth |
| Unit pricing | Low and under generic pressure |
| Gross margin | Vulnerable to sterile-manufacturing costs |
| Revenue volatility | Higher during shortages and contract changes |
| New-product upside | Limited without differentiated delivery or packaging |
| Capital requirements | High relative to product revenue because sterile facilities require compliance investment |
| Customer concentration | Potentially high through group purchasing organizations and hospital systems |
Manufacturers generally do not disclose product-level revenue for preservative-free methotrexate. Financial exposure is usually embedded in broader reporting categories such as generic injectables, hospital products, oncology products, or sterile pharmaceuticals.
Revenue scenarios
Base case
Under normal supply conditions, revenue is likely to remain flat to modestly positive. Volume growth may offset price erosion, but the product does not have the characteristics of a high-growth pharmaceutical asset.
Upside case
Revenue can increase when:
- A competitor exits the market
- A shortage shifts hospital contracts to an available supplier
- The manufacturer adds a new vial size or concentration
- The product gains preferred status in a hospital or group purchasing contract
- Oncology treatment volumes increase
Shortage-driven gains may be temporary. Buyers often reallocate volume after supply normalizes.
Downside case
Revenue and margin can decline because of:
- FDA manufacturing observations or warning letters
- Batch recalls
- Loss of a major hospital contract
- Competitor re-entry following a shortage
- Rising glass, stopper, labor, or quality-control costs
- Unfavorable reimbursement or purchasing changes
- Substitution with oral, prefilled, or alternative injectable products
Which companies manufacture or market methotrexate sodium preservative free?
The U.S. supply base has included major generic and injectable manufacturers such as Pfizer, Hikma Pharmaceuticals, Fresenius Kabi, and other FDA-approved suppliers, depending on the product strength and market period. Manufacturer participation changes as companies discontinue presentations, transfer applications, or alter distribution arrangements.
Pfizer markets methotrexate injection products under its hospital and generic portfolio. Hikma and Fresenius Kabi have also participated in injectable generic markets that include oncology and hospital products. The relevant competitive analysis must be conducted at the National Drug Code and presentation level rather than only at the active-ingredient level.
Competitive structure
Competition is generally based on:
- Reliable supply
- FDA-compliant sterile manufacturing
- Contract price
- Available vial sizes
- Preservative-free labeling
- Back-order performance
- Distribution reach
- Ability to support hospital formulary requirements
Brand recognition has limited value in routine generic procurement. A manufacturer with dependable supply can obtain commercial leverage even when its list price is not the lowest.
Is methotrexate sodium preservative free subject to patent or exclusivity protection?
Methotrexate sodium preservative free is not generally protected by a meaningful active-ingredient patent estate in the United States. Methotrexate is an old molecule, and the commercial products are primarily abbreviated new drug application products or mature injectable presentations.
| Protection category | Commercial relevance |
|---|---|
| Active-ingredient patent | Effectively exhausted for standard methotrexate |
| Basic formulation patent | Generally limited for established injectable products |
| Orange Book exclusivity | Usually absent or immaterial for mature generic products |
| Method-of-use patent | May exist for specific branded or novel indications, but generally does not block routine generic injectable supply |
| Manufacturing know-how | Potentially important, especially for sterile filling and quality control |
| Regulatory exclusivity | Not a major barrier for standard generic presentations |
The principal barriers are regulatory and operational rather than patent-based. A manufacturer may hold application-specific intellectual property covering a container, device, concentration, or manufacturing process, but those rights do not normally create broad market exclusivity for methotrexate sodium preservative-free injection.
What is the Orange Book status of methotrexate sodium preservative free?
The FDA Orange Book is relevant to approved drug products that have listed patents or exclusivity. Standard generic methotrexate sodium injectable products generally do not carry a commercially meaningful Orange Book patent shield comparable to newer branded drugs.
The relevant regulatory records are:
- FDA Orange Book listings
- Drugs@FDA approval histories
- FDA-approved product labeling
- National Drug Code directories
- FDA drug shortage records
- Manufacturer-specific ANDA information where publicly available
A product-level Orange Book review must distinguish between an approved reference product and individual generic listings. The absence of a listed patent does not eliminate regulatory obligations; it means that patent-based launch barriers are not the primary competitive issue.
Are there Paragraph IV challenges for methotrexate sodium preservative free?
Paragraph IV litigation is not a central market feature for this mature generic injectable segment. Paragraph IV certifications are most commercially important when a generic applicant challenges an active patent listed for a branded reference product. Standard preservative-free methotrexate injection products generally lack the type of active, high-value patent estate that produces sustained Paragraph IV litigation.
Competitive disputes are more likely to involve:
- ANDA approval timing
- Product discontinuation
- Manufacturing compliance
- Drug shortage allocation
- Contract awards
- Labeling and presentation differences
- Patent disputes involving a novel delivery system rather than conventional methotrexate injection
When does methotrexate sodium preservative free lose exclusivity?
For standard generic methotrexate sodium preservative-free injection, the practical exclusivity period has already expired. The active ingredient and conventional injectable use are long-established.
There is no single universal expiration date because the market contains multiple products, strengths, manufacturers, ANDAs, and jurisdictions. Any remaining protection would normally relate to a specific product configuration, device, process, or branded delivery system rather than conventional methotrexate sodium injection itself.
The commercial timeline is therefore governed by supply entry and exit:
| Timeline | Market event |
|---|---|
| Historical period | Active ingredient and conventional use become generic |
| Current market | Multiple approved or historically approved suppliers, with variable availability |
| Short-term | Price and share move with shortages, contracts, and plant capacity |
| Long-term | Demand remains mature unless a new delivery system changes treatment patterns |
What formulation patents protect methotrexate products?
Formulation and delivery patents are more relevant to products such as prefilled syringes, autoinjectors, concentrated formulations, and specialty delivery systems than to basic preservative-free vials.
Potentially protectable elements include:
- Autoinjector mechanics
- Prefilled syringe configuration
- Needle-shield systems
- Stability-enhancing excipients
- Concentration and viscosity controls
- Container-closure systems
- Administration protocols
- Combination products
- Device-enabled dose selection
These rights may protect a commercial product without creating exclusivity over methotrexate itself. Rasuvo, for example, is a methotrexate injection product with an autoinjector-based delivery model. It competes in a different commercial segment from hospital preservative-free methotrexate sodium vials and should not be treated as a direct equivalent in financial analysis.[2]
How do shortages affect methotrexate sodium preservative-free pricing?
Shortages are the main source of short-term market dislocation. FDA and ASHP shortage records have identified methotrexate injection availability issues at various times, often involving specific strengths, suppliers, or container sizes rather than a complete disappearance of every methotrexate product.[3][4]
Shortage effects include:
- Temporary price increases
- Emergency purchasing from secondary distributors
- Hospital allocation controls
- Substitution to different vial sizes or concentrations
- Increased use of oral or alternative injectable products
- Higher inventory carrying costs
- Greater willingness to sign multi-source supply agreements
The economic value of reliable supply can exceed the value of a small list-price difference. Hospitals may retain a supplier with a stronger fill rate because switching costs include formulary changes, pharmacy workflow revisions, staff training, and clinical risk management.
What manufacturing and intellectual-property barriers affect the market?
The largest barriers are sterile manufacturing and regulatory compliance.
Manufacturing barriers
Methotrexate injection requires:
- Validated sterile processing
- Aseptic filling and packaging
- Environmental monitoring
- Container-closure integrity testing
- Potency and impurity testing
- Particulate control
- Robust quality systems
- Compliance with current good manufacturing practices
Sterile injectables have higher failure costs than oral solid products. A single contaminated batch, inspection finding, or component shortage can remove meaningful supply from the market.
Intellectual-property barriers
IP can affect differentiated presentations, but it is less important for the standard vial. Relevant rights may cover:
- Delivery devices
- Prefilled formats
- Packaging
- Manufacturing methods
- Stability profiles
- Specific combinations or treatment regimens
Freedom-to-operate analysis should be conducted separately for the active ingredient, formulation, container, device, and method of use.
How does preservative-free injectable methotrexate compare with other methotrexate products?
| Product type | Primary channel | Competitive position | Financial profile |
|---|---|---|---|
| Preservative-free vial | Hospitals and clinics | Protocol-driven, supply-sensitive | Low price, operationally important |
| Preservative-containing vial | Institutional use where appropriate | Limited by route and patient requirements | Commodity pricing |
| Oral tablet | Retail, specialty, institutional | Broad chronic-use base | High volume, low unit price |
| Oral solution | Pediatric and specialty use | Niche presentation | Limited volume |
| Prefilled syringe | Specialty and office administration | Convenience and dosing differentiation | Higher price potential |
| Autoinjector | Rheumatology and self-administration | Device-driven differentiation | Higher commercial value, higher development cost |
Preservative-free injectable methotrexate is more exposed to sterile-supply risk than oral tablets and less commercially differentiated than autoinjector products.
What generic entry risks exist for methotrexate sodium preservative free?
Generic entry risk is high in principle because the molecule is mature and conventional injectable products have limited patent protection. In practice, entry can remain constrained by economics.
A new entrant must absorb:
- ANDA development and approval costs
- Sterile manufacturing validation
- Facility maintenance
- Pharmacovigilance and quality systems
- Commercial discounts
- Distribution and inventory costs
- Potentially low annual revenue
This creates a paradox: legal entry barriers are low, but sustainable economic entry can be difficult. A small number of suppliers may remain active because the market does not support unlimited sterile injectable competition.
What licensing deals affect methotrexate sodium preservative free?
Publicly disclosed licensing transactions focused specifically on conventional methotrexate sodium preservative-free injection are limited. Commercial arrangements are more likely to involve:
- Contract manufacturing
- Authorized generic distribution
- Portfolio acquisitions
- Hospital supply contracts
- Device licensing for prefilled or autoinjector products
- Regional distribution rights
Large pharmaceutical companies often disclose portfolio-level transactions without separately reporting methotrexate injection economics. Licensing value is therefore more likely to arise from manufacturing access or device differentiation than from ownership of methotrexate chemistry.
What is the regulatory status of methotrexate sodium preservative free?
FDA-regulated products must have approved applications and labeling appropriate to the specific strength, route, dosage form, and preservative status. Preservative-free labeling is clinically material and cannot be inferred solely from the active ingredient name.
Regulatory review should confirm:
- Current marketing status
- Approved strength and concentration
- Single-dose or multidose presentation
- Intrathecal labeling, if applicable
- Preservative status
- Current manufacturer and distributor
- FDA shortage status
- Recalls or safety communications
- ANDA or NDA history
- Labeling revisions
Hospital buyers should avoid treating all methotrexate injections as interchangeable. Concentration, route, preservative content, and container size can affect clinical use.
What is the investment outlook for methotrexate sodium preservative free?
The product is unlikely to generate material growth through traditional price expansion or patent protection. Its investment value depends on portfolio fit.
It may be attractive when a manufacturer has:
- Excess sterile capacity
- Strong hospital distribution
- Existing oncology contracts
- A reliable injectable supply chain
- Ability to produce multiple methotrexate presentations
- Low incremental manufacturing cost
- A strategy focused on shortage-prone generic injectables
It is less attractive as a standalone growth asset because:
- Product-level revenue is limited and rarely disclosed
- Price competition is persistent
- Patent barriers are weak
- Hospital contracts can be lost quickly
- Manufacturing failures have disproportionate financial impact
- Shortage-related gains may not persist
The strongest commercial position belongs to suppliers that combine regulatory compliance with dependable fill rates and broad hospital access.
Key Takeaways
- Methotrexate sodium preservative free is a mature generic injectable, not a patent-led growth product.
- Demand is stable because methotrexate remains embedded in oncology, rheumatology, dermatology, and ectopic-pregnancy treatment.
- Product-specific revenue is generally not publicly reported.
- Financial performance depends on supply continuity, sterile manufacturing, hospital contracts, and shortage conditions.
- Conventional methotrexate injection has little meaningful remaining patent or regulatory exclusivity.
- Paragraph IV litigation is not a primary market driver.
- Formulation and device IP matters more for prefilled syringes and autoinjectors than for standard vials.
- Generic entry is legally feasible but economically constrained by sterile manufacturing costs and low prices.
- The best commercial opportunity is portfolio-based: reliable hospital supply, multiple presentations, and efficient sterile capacity.
FAQs
Is preservative-free methotrexate safer than methotrexate with preservatives?
Preservative-free methotrexate is required or preferred for certain routes and clinical settings because preservatives can create safety concerns. The appropriate product depends on the approved labeling, route, dose, and clinical protocol.
Can preservative-free methotrexate sodium be used intrathecally?
Only a product specifically labeled and approved for intrathecal use should be administered intrathecally. Preservative status alone does not establish suitability.
Does methotrexate sodium preservative free have biosimilar competition?
No. Methotrexate is a small-molecule drug, so competition occurs through generic drug pathways rather than biosimilar approval pathways.
Why can a mature generic methotrexate product experience shortages?
Sterile injectable production is vulnerable to plant shutdowns, quality failures, component shortages, limited manufacturing capacity, and low market prices that discourage redundant suppliers.
Is methotrexate sodium preservative free a good licensing target?
It is generally more attractive as part of a broader sterile-injectable portfolio than as a standalone licensing asset. Value depends on manufacturing capacity, hospital access, supply reliability, and differentiated packaging.
References
-
U.S. Food and Drug Administration. (2023). Methotrexate injection prescribing information. Drugs@FDA.
-
U.S. Food and Drug Administration. (2023). Rasuvo prescribing information. Drugs@FDA.
-
U.S. Food and Drug Administration. (n.d.). Drug shortages: Methotrexate injection. FDA Drug Shortages Database.
-
American Society of Health-System Pharmacists. (n.d.). Methotrexate injection shortage information. ASHP Drug Shortages Resource Center.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drug database. FDA.
More… ↓
